A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Ciltacabtagene autoleucel (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms CARTIFAN-1
- Sponsors Nanjing Legend Biotech
Most Recent Events
- 27 Aug 2024 According to a GenScript Biotech Corp media release, based on the data from this study, Ciltacabtagene-autoleucel drug has received approval in the China by National Medical Products Administration (NMPA) for the treatment multiple myeloma.
- 23 May 2024 According to a Legend Biotech media release, data from this study will be presented at the 2024 European Hematology Association's (EHA) Hybrid Congress.
- 02 Nov 2023 According to a Legend Biotech media release, data from this study will be presented at the 65th American Society of Hematology Annual Meeting and Exposition.